The Latest Breaking News from Lyra rapeutics

Lyra Therapeutics's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q1, Lyra Therapeutics's (NASDAQ:LYRA) reported sales totaled $5.37 million. Despite a 48.51% increase in earnings, the company posted a loss of $7.01 million.

Benzinga · Jun 10, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022

Upgrades

Benzinga · May 24, 2022

Recap: Lyra Therapeutics Q1 Earnings

  Lyra Therapeutics (NASDAQ:LYRA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 10, 2022